A systematic review of tests predicting ovarian reserve and IVF outcome

#	Paper	IF	Citations
957	Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. **2006**, 12, 6194-202		137
956	Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment?. **2007**, 22, 1932-41		62
955	Management of infertility. **2007**, 335, 608-11		32
954	Predictive value and clinical impact of Basal follicle-stimulating hormone in subfertile, ovulatory women. **2007**, 92, 2163-8		61
953	Unexplained infertility: does it really exist? Does it matter?. **2007**, 22, 2084-7		31
952	Recent advances in female infertility assessment and treatment. **2007**, 2, 501-513		
951	A 47-year-old woman with fertility problems who desires a multiple pregnancy. **2007**, 297, 858-67		11
950	Potential use of biomarkers for analyzing interpopulation and cross-cultural variability in reproductive aging. **2007**, 14, 668-79		7
949	Bibliography. Current world literature. Fertility. **2007**, 19, 289-96		
948	Ovarian Hyperstimulation Syndrome: The Best Approaches for Preven-tion and Treatment: A Mini-Review. **2007**, 3, 49-54		2
947	Female reproductive ageing: current knowledge and future trends. **2007**, 18, 58-65		283
946	Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. **2007**, 22, 2414-21		318
945	Does measuring early basal serum follicular luteinising [correction of lutinising] hormone assist in predicting in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) outcome?. **2007**, 5, 32		2
944	Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. **2007**, 5, 9		91
943	Cumulative live birth rates following IVF in 41- to 43-year-old women presenting with favourable ovarian reserve characteristics. **2007**, 14, 455-63		24
942	Ovarian Ageing and Fertility - Review. **2007**, 3, 63-67		
941	Die ältere Kinderwunschpatientin. **2007**, 40, 766-772		

922	A new approach to ovarian reserve testing. *Fertility and Sterility*, **2008**, 90, 2196-202	4.8	34
921	Ovarian response in women undergoing ovarian stimulation after myomectomy. *Fertility and Sterility*, **2008**, 90, 2004.e19-21	4.8	2
920	The clomiphene citrate challenge test (CCCT) in women with elevated basal FSH: biological significance and predictive value. **2008**, 141, 44-8		5
919	Relevance of basal serum FSH to IVF outcome varies with patient age. **2008**, 17, 10-9		24
918	The road to pluripotence: the research response to the embryonic stem cell debate. **2008**, 17, R3-9		11
917	Interleukin-1 receptor antagonist gene (IL-1RN) polymorphism is a predictive factor of clinical pregnancy after IVF. **2008**, 23, 1200-6		15
916	Selection of patients before and after anticancer treatment for ovarian cryopreservation. **2008**, 23, 869-77		47
915	Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response. **2008**, 23, 1538-44		15
914	The predictive value of ovarian reserve tests for spontaneous pregnancy in subfertile ovulatory women. **2008**, 23, 1800-7		18
913	What next for preimplantation genetic screening? A clinician's perspective. **2008**, 23, 1686-90		10
912	The predictive value of ovarian reserve tests for miscarriage in a population of subfertile ovulatory women. **2009**, 24, 546-52		14
911	Relevance of anti-Mullerian hormone measurement in a routine IVF program. **2008**, 23, 1359-65		172
910	Predicting fertility. **2008**, 11, 109-17		15
909	Relationship of serum antimüllerian hormone concentration to age at menopause. **2008**, 93, 2129-34		204
908	Accuracy of soluble human leukocyte antigen-G for predicting pregnancy among women undergoing infertility treatment: meta-analysis. *Human Reproduction Update*, **2008**, 14, 209-18	15.8	50
907	The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. *Human Reproduction Update*, **2008**, 14, 95-100	15.8	87
906	Infertility in Practice. **2008**,		10
905	Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. **2008**, 23, 2475-83		84

904	Ovarian reserve screening: what the general gynecologist should know. **2008**, 4, 291-300	1
903	Anti-Müllerian hormone as a marker of ovarian reserve: an update. **2008**, 4, 137-41	10
902	Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. **2009**, 24, 867-75	259
901	3D ultrasound in gynecology and reproductive medicine. **2008**, 4, 501-16	12
900	A survey of clinicians' views on age and access to IVF and the use of tests of ovarian reserve prior to IVF in the United Kingdom. **2008**, 11, 23-7	7
899	Age-specific ovarian function. **2008**, 3, 595-600	2
898	How old are your eggs?. **2008**, 20, 540-4	12
897	Utility of serum antimüllerian hormone/Müllerian-inhibiting substance for predicting ovarian reserve in older women. **2008**, 15, 824-6	1
896	Implications of diminished ovarian reserve (DOR) extend well beyond reproductive concerns. **2008**, 15, 1086-94	35
895	Choices of stimulation for low responders in IVF. **2008**, 3, 531-538	
894	The Prediction and Management of Poor Responders in ART. 428-442	1
893	[Use of antral follicle count to predict the response pattern in controlled ovarian hyperstimulation cycles with GnRH antagonist]. **2008**, 30, 36-41	2
892	Defining human embryo phenotypes by cohort-specific prognostic factors. **2008**, 3, e2562	24
891	Introduction to preimplantation genetic diagnosis. 1-47	1
890	[Evaluation of basal FSH serum levels in infertile patients with deep ovarian endometriosis who underwent surgery]. **2009**, 31, 349-52	2
889	EVALUACIÓN PRÁCTICA DE LAS PRUEBAS PARA INVESTIGAR EL FACTOR OVULATORIO COMO PARTE DEL ESTUDIO INICIAL EN LAS PACIENTES CON SUBFERTILIDAD. **2009**, 74,	
888	Aplicações das dosagens de inibinas em Ginecologia e Obstetrícia. **2009**, 31,	1
887	Screening for early ovarian ageing. 201-210	1

886   Future fertility insurance. 237-242

885   Evidence-based and cost-effective fertility investigation and treatment of older women: moving beyond NICE. 293-302

884   Ultrasound tests of ovarian reserve; a systematic review of accuracy in predicting fertility outcomes. **2009**, 12, 95-106   27

883   Clinical biochemistry of assisted conception. **2009**, 46, 197-204   0

882   The predictive value of the automated quantification of the number and size of small antral follicles in women undergoing ART. **2009**, 24, 2124-32   18

881   Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist?. **2009**, 24, 2902-9   86

880   High basal LH levels in combination with low basal FSH levels are associated with high success rates at assisted reproduction. **2009**, 24, 2755-9   22

879   Fertility in female childhood cancer survivors. **2009**, 15, 135-158   13

878   Orthotopic and heterotopic ovarian tissue transplantation. *Human Reproduction Update*, **2009**, 15, 649-65   15.8   198

877   Anti-Mullerian hormone (AMH): what do we still need to know?. **2009**, 24, 2264-75   236

876   Approaches to improve the diagnosis and management of infertility. *Human Reproduction Update*, **2009**, 15, 391-408   15.8   58

875   Individual patient data meta-analysis of diagnostic and prognostic studies in obstetrics, gynaecology and reproductive medicine. **2009**, 9, 22   29

874   Management of premature ovarian failure. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2009**, 23, 129-40   4.6   94

873   Breast Cancer in Young Women and its Impact on Reproductive Function. **2009**, 6, 200-208   4

872   Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Mllerian hormone versus small antral follicle count (2-6 mm). *Journal of Assisted Reproduction and Genetics*, **2009**, 26, 319-25   3.4   49

871   Serum anti-Mllerian hormone predicts ovarian response and cycle outcome in IVF patients. *Journal of Assisted Reproduction and Genetics*, **2009**, 26, 383-9   3.4   54

870   Prise en charge de lhftondit'dans les troubles de ljaculation: avis conjoints de landrologue, du biologiste et du gyntologue. **2009**, 19, 209-217

869   Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. **2009**, 53, 296-302   63

868	Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome?. **2009**, 33, 583-91		18
867	Ovarian reserve screening in infertility: practical applications and theoretical directions for research. **2009**, 146, 30-6		81
866	Cryopreservation of oocytes in a young woman with severe and symptomatic endometriosis: a new indication for fertility preservation. *Fertility and Sterility*, **2009**, 91, 293.e1-3	4.8	45
865	The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. *Fertility and Sterility*, **2009**, 91, 705-14	4.8	376
864	Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study. *Fertility and Sterility*, **2009**, 91, 767-76	4.8	18
863	How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. *Fertility and Sterility*, **2009**, 91, 749-66	4.8	165
862	Do stimulation characteristics of the first in vitro fertilization cycle predict pregnancy in women of 40 years old and over?. *Fertility and Sterility*, **2009**, 91, 1311-3	4.8	8
861	Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. *Fertility and Sterility*, **2009**, 91, 2616-9	4.8	49
860	Serum inhibin B during controlled ovarian hyperstimulation: an additional criterion for deciding whether to proceed with egg retrieval. *Fertility and Sterility*, **2009**, 91, 2419-25	4.8	6
859	Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. *Fertility and Sterility*, **2009**, 91, 2437-44	4.8	52
858	The correlation between basal serum follicle-stimulating hormone levels before embryo cryopreservation and the clinical outcome of frozen embryo transfers. *Fertility and Sterility*, **2009**, 92, 1269-1275	4.8	11
857	Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. *Fertility and Sterility*, **2009**, 92, 1586-93	4.8	201
856	Elective single embryo transfer: a 6-year progressive implementation of 784 single blastocyst transfers and the influence of payment method on patient choice. *Fertility and Sterility*, **2009**, 92, 1895-906	4.8	91
855	The three-dimensional ultrasonographic ovarian vascularity of women developing poor ovarian response during assisted reproduction treatment and its predictive value. *Fertility and Sterility*, **2009**, 92, 1862-9	4.8	20
854	Pregnancy in classic galactosemia despite undetectable anti-Müllerian hormone. *Fertility and Sterility*, **2009**, 91, 1293.e13-6	4.8	26
853	Negligible serum anti-müllerian hormone: pregnancy and birth after a 1-month course of an oral contraceptive, ovarian hyperstimulation, and intracytoplasmic sperm injection. *Fertility and Sterility*, **2009**, 92, 395.e9-395.e12	4.8	13
852	[The role of ultrasound examination to evaluate ovarian reserve of infertile patients]. **2009**, 37, 425-31		3
851	Testing ovarian reserve to predict age at menopause. **2009**, 63, 280-91		100

850	Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy. **2009**, 18, 717-34		33
849	Individual ovarian volumes obtained from 2-dimensional and 3-dimensional ultrasound lack precision. **2009**, 18, 348-51		13
848	Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. **2009**, 18, 195-204		84
847	HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study. **2009**, 18, 205-8		7
846	Feasibility of fertility preservation in young females with Turner syndrome. **2009**, 18, 290-5		49
845	Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. **2009**, 7, 100		56
844	Biological versus chronological ovarian age: implications for assisted reproductive technology. **2009**, 7, 101		86
843	Endometrial thickness, Caucasian ethnicity, and age predict clinical pregnancy following fresh blastocyst embryo transfer: a retrospective cohort. **2009**, 7, 33		46
842	Ovarian aging: mechanisms and clinical consequences. **2009**, 30, 465-93		629
841	Medical Approaches to Ovarian Stimulation for Infertility. **2009**, 689-724		2
840	Breast cancer in young women and its impact on reproductive function. *Human Reproduction Update*, **2009**, 15, 323-39	15.8	110
839	The Ovarian Life Cycle. **2009**, 155-190		9
838	Cost-effectiveness of vasectomy reversal. **2009**, 36, 391-6		19
837	Influence of lifestyle factors on fertility rate. **2009**, 4, 635-646		1
836	An internet-based prospective study of body size and time-to-pregnancy. **2010**, 25, 253-64		172
835	Pršervation de la fertilit'fřinine et cancer. **2010**, 5, 1-12		1
834	Prognostic Role of Ovarian Reserve Testing. **2010**, 6, 267-272		
833	Effect of obesity on parameters of ovarian reserve in premenopausal women. **2010**, 32, 687-90		41

814	Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine. *Human Reproduction Update*, **2010**, 16, 561-7	15.8	33
813	Ultrasound and its role in assisted reproduction treatment. **2010**, 2, 135-150		1
812	Inhibin B and anti-Mullerian hormone as markers of persistent spermatogenesis in men with non-obstructive azoospermia: a meta-analysis of diagnostic accuracy studies. *Human Reproduction Update*, **2010**, 16, 713-24	15.8	55
811	Fertility and age. **2010**, 3, 121-3		23
810	Assessment of theca cell function prior to controlled ovarian stimulation: the predictive value of serum basal/stimulated steroid levels. **2010**, 25, 228-34		20
809	A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVF-treated women. **2010**, 25, 552-8		40
808	Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities?. **2010**, 30, 393-6		8
807	Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. **2010**, 28, 463-7		10
806	Early menopause: primary ovarian insufficiency and surgical menopause. **2010**, 28, 360-9		32
805	Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed?. *Human Reproduction Update*, **2010**, 16, 617-30	15.8	167
804	Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype. **2010**, 20, 610-8		8
803	Anti-Mllerian hormone and polycystic ovary syndrome: a mountain too high?. **2010**, 139, 825-33		137
802	Discordances between follicle stimulating hormone (FSH) and anti-Mllerian hormone (AMH) in female infertility. **2010**, 8, 64		38
801	Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). *Human Reproduction Update*, **2010**, 16, 113-30	15.8	608
800	Increased basal FSH levels as predictors of low-quality follicles in infertile women with endometriosis. **2010**, 110, 208-12		6
799	EMAS position statement: Managing women with premature ovarian failure. **2010**, 67, 91-3		100
798	The use of anti-Mllerian hormone and antral follicle count to predict the potential of oocytes and embryos. **2010**, 150, 166-70		85
797	Do ovarian reserve tests predict miscarriage in women undergoing assisted reproduction treatment?. **2010**, 153, 181-4		8

796	A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. *Fertility and Sterility*, **2010**, 93, 855-64	4.8	189
795	True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement. *Fertility and Sterility*, **2010**, 93, 995-8	4.8	33
794	Cancer and fecundity issues mandate a multidisciplinary approach. *Fertility and Sterility*, **2010**, 93, 691-6	4.8	17
793	Hypertensive pregnancy complications in poor and normal responders after in vitro fertilization. *Fertility and Sterility*, **2010**, 93, 652-7	4.8	12
792	A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. *Fertility and Sterility*, **2010**, 94, 655-61	4.8	29
791	The antral follicle count: practical recommendations for better standardization. *Fertility and Sterility*, **2010**, 94, 1044-51	4.8	234
790	Multivariate analysis of the association between oocyte donor characteristics, including basal follicle stimulating hormone (FSH) and age, and IVF cycle outcomes. *Fertility and Sterility*, **2010**, 94, 1292-1295	4.8	14
789	Analysis of 2,386 consecutive cycles of in vitro fertilization or intracytoplasmic sperm injection using autologous oocytes in women aged 40 years and above. *Fertility and Sterility*, **2010**, 94, 1707-12	4.8	34
788	The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation. *Fertility and Sterility*, **2010**, 94, 1775-81	4.8	66
787	Antral follicle count as a predictor of hyperresponse in controlled ovarian hyperstimulation/intrauterine insemination in unexplained sterility. *Fertility and Sterility*, **2010**, 94, 1105-7	4.8	2
786	Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. *Fertility and Sterility*, **2010**, 94, 2177-81	4.8	34
785	Effect of different types of ovarian cyst on antral follicle count. *Fertility and Sterility*, **2010**, 94, 2338-9	4.8	20
784	Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression. *Fertility and Sterility*, **2010**, 94, 2590-5	4.8	14
783	G546A polymorphism of growth differentiation factor-9 contributes to the poor outcome of ovarian stimulation in women with diminished ovarian reserve. *Fertility and Sterility*, **2010**, 94, 2490-2	4.8	21
782	Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. *Fertility and Sterility*, **2010**, 94, 2824-7	4.8	105
781	Serum anti-Müllerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. *Fertility and Sterility*, **2010**, 94, 2846-9	4.8	116
780	Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation. **2010**, 20, 191-200		29
779	Pre-stimulation parameters predicting live birth after IVF in the long GnRH agonist protocol. **2010**, 20, 572-81		7

778	Effect of cigarette smoking upon reproductive hormones in women of reproductive age: a retrospective analysis. **2010**, 20, 861-5		39
777	Are US results for assisted reproduction better than the rest? Is it a question of competence or policies?. **2010**, 21, 624-30		7
776	Single nucleotide polymorphisms in the anti-Müllerian hormone signalling pathway do not determine high or low response to ovarian stimulation. **2010**, 21, 616-23		28
775	Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. **2010**, 21, 593-601		47
774	The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. **2010**, 21, 757-61		49
773	Primary ovarian insufficiency. **2010**, 376, 911-21		427
772	[Evaluation of the ovarian reserve]. **2010**, 39, S27-33		3
771	Effects of excision of ovarian endometrioma on the antral follicle count and collected oocytes for in vitro fertilization. *Fertility and Sterility*, **2010**, 94, 2340-2	4.8	50
770	Single-nucleotide polymorphisms in the FSH receptor gene and ovarian performance: future role in IVF. **2010**, 13, 72-8		22
769	Evidence-based management of poor ovarian response. **2010**, 1205, 199-206		27
768	Chronic psychosocial stressors are detrimental to ovarian reserve: a study of infertile women. **2010**, 31, 130-9		26
767	Small antral follicle count (2-5 mm) and ovarian volume for prediction of pregnancy in in vitro fertilization cycles. **2011**, 27, 748-52		7
766	Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles. **2011**, 14, 246-53		21
765	Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. **2011**, 26, 3413-23		85
764	Factors predicting the cumulative outcome of IVF/ICSI treatment: a multivariable analysis of 2450 patients. **2011**, 26, 2532-40		71
763	Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. **2011**, 22 Suppl 1, S23-31		6
762	Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. **2011**, 22 Suppl 1, S73-82		25
761	Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. **2011**, 26, 1768-74		548

742	Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. *Fertility and Sterility*, **2011**, 96, 126-133.e3	4.8	51
741	Bisphenol A exposure reduces the estradiol response to gonadotropin stimulation during in vitro fertilization. *Fertility and Sterility*, **2011**, 96, 672-677.e2	4.8	89
740	Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. *Fertility and Sterility*, **2011**, 96, 594-9	4.8	46
739	Cost effectiveness of ovarian reserve testing in in vitro fertilization: a Markov decision-analytic model. *Fertility and Sterility*, **2011**, 96, 889-94	4.8	16
738	A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?. *Fertility and Sterility*, **2011**, 96, 1058-61.e7	4.8	152
737	Reproductive banking and older women. **2011**, 70, 3-4		3
736	[Serum AMH level is not a predictive value for IVF in modified natural cycle: analysis of 342 cycles]. **2011**, 40, 205-10		11
735	[Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment]. **2011**, 40, 593-611		18
734	No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. **2011**, 23, 457-65		33
733	What strategies are the most effective in optimizing IVF outcome in patients with advanced maternal age?. **2011**, 6, 591-598		1
732	ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. **2011**, 26, 1616-24		1046
731	Poor responders to controlled ovarian hyperstimulation for in vitro fertilisation (IVF). **2011**, 14, 230-45		9
730	A single nucleotide polymorphism in BMP15 is associated with high response to ovarian stimulation. **2011**, 23, 97-104		38
729	Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. **2011**, 23, 150-9		32
728	Laparoscopic stripping of endometriomas negatively affects ovarian follicular reserve even if performed by experienced surgeons. **2011**, 23, 740-6		112
727	The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. **2011**, 10, 95-103		39
726	Pre-treatment hormone assessment to optimize IVF outcomes. 1-6		
725	Molecular and cellular integrity of cultured follicles. 389-396		

724	The evolution of ART. 1-10		
723	In vitro maturation of GV oocytes. 421-430		1
722	Ovarian endometriomas:. 18-26		1
721	The effect of chemotherapy and radiotherapy on the human reproductive system. 11-22		
720	Ovarian aging: latest thoughts on assessment and management. **2011**, 23, 427-34		26
719	Advanced reproductive age and fertility. **2011**, 33, 1165-1175		117
718	Reproductive capacity in iron overloaded women with thalassemia major. *Blood*, **2011**, 118, 2878-81	2.2	43
717	Normal Ovarian Function and Assessment of Ovarian Reserve in Children and Young People. **2011**, 331-349		1
716	Deep pelvic endometriosis negatively affects ovarian reserve and the number of oocytes retrieved for in vitro fertilization. **2011**, 90, 878-84		33
715	The role of anti-Mullerian hormone in assisted reproductive medicine. **2011**, 16, 103-106		
714	Persistent endometrial polyps may affect the pregnancy rate in patients undergoing intrauterine insemination. **2011**, 16, 259-264		9
713	Surgical measures for endometriosis-related infertility: a plea for research. **2011**, 32 Suppl 3, S238-42		39
712	Recurrent endometrioma and ovarian reserve: biological connection or surgical paradox?. **2011**, 204, 529.e1-5		21
711	Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment. *Journal of Assisted Reproduction and Genetics*, **2011**, 28, 501-8	3.4	26
710	The value of human chorionic gonadotropin stimulation test in predicting ovarian response during in-vitro fertilization. *Journal of Assisted Reproduction and Genetics*, **2011**, 28, 893-9	3.4	2
709	Das Anti-Müler-Hormon. **2011**, 9, 238-246		4
708	Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients. **2011**, 10, 9-14		10
707	Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. **2011**, 9, 112		43

706	The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age. **2011**, 9, 115		26
705	Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. **2011**, 9, 82		51
704	The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. **2011**, 26, 904-10		144
703	AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. *Human Reproduction Update*, **2011**, 17, 46-54	15.8	291
702	Rapid determination of serological cytokine biomarkers for hepatitis B virus-related hepatocellular carcinoma using antibody microarrays. **2011**, 43, 45-51		14
701	Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. **2011**, 26, 2353-62		113
700	Unoperated ovarian endometriomas and responsiveness to hyperstimulation. **2011**, 26, 1356-61		51
699	Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. **2011**, 26, 414-22		69
698	Do female translocations influence the ovarian response pattern to controlled ovarian stimulation in preimplantation genetic diagnosis?. **2011**, 26, 1232-40		9
697	Implications of blood type for ovarian reserve. **2011**, 26, 2513-7		28
696	Anti-Mullerian hormone--is it a crystal ball for predicting ovarian ageing?. **2011**, 26, 2925-32		61
695	Role of combined oral contraceptives in women undergoing assisted reproduction treatment. **2011**, 6, 495-499		
694	Ovarian reserve tests. **2011**, 4, 108-13		52
693	Reproduction in females: the role of the early life environment. *Human Reproduction Update*, **2011**, 17, 210-27	15.8	55
692	Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve. **2012**, 5, 274-8		13
691	The Clinical Utility of the Concept of Jing in Chinese Reproductive Medicine. **2012**, 7, 421-454		1
690	Ovarian volume correlates strongly with the number of nongrowing follicles in the human ovary. **2012**, 2012, 305025		16
689	The modern infertility evaluation. **2012**, 55, 692-705		10

688   Antral follicular count is a better indicator for the assessment of ovarian reserve. **2012**, 2, 126-132

687   Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with type 2 diabetes mellitus. **2012**, 97, 261-9   38

686   Prognostic testing for ovarian reserve. **2012**, 41-50

685   Ultrasonography in assisted reproduction. **2012**, 225-241

684   Treatment strategies in assisted reproduction for the poor responder patient. **2012**, 162-207   2

683   Initial investigation of the infertile couple. **2012**, 31-40

682   Evaluation of ovarian reserve in infertile patients. **2012**, 13, 196-203   17

681   Ovarian reserve assessment for infertility investigation. **2012**, 2012, 576385   17

680   Does Fsh/lh Ratio In The Serum On The Third Day Of The Cycle Predict Icsi Success In Women With Normal Day 3 Fsh Levels?. **2012**,

679   Minkowski-Weyl Priors for Models With Parameter Constraints: An Analysis of the BioCycle Study. **2012**, 107, 1395-1409   7

678   Simple adaptations to the Templeton model for IVF outcome prediction make it current and clinically useful. **2012**, 27, 2971-8   25

677   Endocrinological insights into different in vitro fertilization treatment aspects. **2012**, 7, 419-432   1

676   Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. **2012**, 2012, 291-292

675   A new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulation. **2012**, 10, 94   19

674   DHEA for poor responders: can treatment be justified in the absence of evidence?. **2012**, 25, 103-7   9

673   Anti-Müllerian hormone: clairvoyance or crystal clear?. **2012**, 27, 631-6   76

672   Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertility and Sterility*, **2012**, 98, 1407-15   4.8   110

671   Detrimental effects of high-dose gonadotropin on outcome of IVF: making a case for gentle ovarian stimulation strategies. *Reproductive Sciences*, **2012**, 19, 718-24   3   14

670	Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment. *Journal of Assisted Reproduction and Genetics*, **2012**, 29, 797-802	3.4	8
669	Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. *Fertility and Sterility*, **2012**, 98, 657-63	4.8	67
668	Accumulation of oocytes: a new strategy for managing low-responder patients. **2012**, 24, 424-32		108
667	Adenomyosis reduces pregnancy rates in infertile women undergoing IVF. **2012**, 25, 273-7		78
666	Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. **2012**, 25, 612-9		96
665	Female Fertility Assessment. **2012**, 1, 174-181		2
664	Serum anti-Müllerian hormone and basal serum FSH as predictors of poor ovarian response in assisted conception cycles. **2012**, 17, 283-289		1
663	Correlations between antral follicle count and ultrasonographic ovarian parameters and clinical variables and outcomes in IVF cycles. **2012**, 28, 432-5		14
662	[Reproductive aging]. **2012**, 154, 47-9		1
661	I marcatori di riserva ovarica nella medicina della riproduzione. **2012**, 13, 169-173		
660	Valores de hormona antimülleriana (HAM) y recuento de folículos antrales (RFA) en casos con fallo reproductivo previo. **2012**, 55, 8-14		
659	[Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response to controlled ovarian hyperstimulation? An analysis of 142 cancellations]. **2012**, 41, 41-7		11
658	[Intra-uterine insemination outcomes according to the serum AMH level on day 3]. **2012**, 41, 122-7		7
657	Advanced reproductive age and fertility: no. 269, November 2011. **2012**, 117, 95-102		95
656	Follicle-stimulating hormone receptor gene polymorphisms are not associated with ovarian reserve markers. *Fertility and Sterility*, **2012**, 97, 677-81	4.8	38
655	Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimüllerian hormone levels. *Fertility and Sterility*, **2012**, 97, 1472-8	4.8	132
654	Diagnostic evaluation of the infertile female: a committee opinion. *Fertility and Sterility*, **2012**, 98, 302-7	4.8	117
653	The CC-allele of the PvuII polymorphic variant in intron 1 of the œstrogen receptor gene is significantly more prevalent among infertile women at risk of premature ovarian aging. *Fertility and Sterility*, **2012**, 98, 965-72.e1-5	4.8	18

652	High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. *Fertility and Sterility*, **2012**, 98, 1037-42	4.8	24
651	Predictors of spontaneous reduction in multiple pregnancies conceived following assisted reproductive technology. **2012**, 162, 174-7		2
650	[Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?]. **2012**, 40, 411-8		10
649	The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. **2012**, 12, 29		43
648	Clomiphene citrate versus high doses of gonadotropins for in vitro fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial. **2012**, 10, 114		23
647	Waiting for an elevated FSH--too late a marker of reduced ovarian reserve?. **2012**, 52, 460-4		13
646	Demographics of infertility and management of unexplained infertility. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2012**, 26, 729-38	4.6	25
645	In vitro fertilisation treatment and factors affecting success. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2012**, 26, 777-88	4.6	29
644	Women with one ovary in assisted reproduction technologies: a review of the literature. *Archives of Gynecology and Obstetrics*, **2012**, 286, 1041-7	2.5	4
643	Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. *Archives of Gynecology and Obstetrics*, **2012**, 286, 667-70	2.5	85
642	Bone morphogenetic protein-15 in follicle fluid combined with age may differentiate between successful and unsuccessful poor ovarian responders. **2012**, 10, 116		16
641	Blood cell mitochondrial DNA content and premature ovarian aging. **2012**, 7, e42423		27
640	Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?. **2012**, 7, e44571		32
639	[Correlation between age and antral follicles count in infertile women]. **2012**, 34, 184-8		2
638	Ovarian reserve in young women of reproductive age with Crohn's disease. **2012**, 18, 1515-22		37
637	Age-related distributions of anti-Müllerian hormone level and anti-Müllerian hormone models. **2012**, 91, 970-5		31
636	Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization. *Journal of Assisted Reproduction and Genetics*, **2012**, 29, 117-25	3.4	14
635	Elevated day 3 FSH/LH ratio: a marker to predict IVF outcome in young and older women. *Journal of Assisted Reproduction and Genetics*, **2012**, 29, 231-6	3.4	15

634	Predictive value of hormonal parameters for live birth in women with unexplained infertility and male infertility. **2013**, 11, 61		12
633	Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. **2013**, 6, 11		44
632	Coupled Somatic Cell Kinetics and Germ Cell Growth: Multiscale Model-Based Insight on Ovarian Follicular Development. **2013**, 11, 719-746		9
631	The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment. *Journal of Assisted Reproduction and Genetics*, **2013**, 30, 821-5	3.4	21
630	Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. *Journal of Assisted Reproduction and Genetics*, **2013**, 30, 657-65	3.4	82
629	What is the best treatment option for infertile women aged 40 and over?. *Journal of Assisted Reproduction and Genetics*, **2013**, 30, 667-71	3.4	19
628	Does obesity compromise ovarian reserve markers? A clinician's perspective. *Archives of Gynecology and Obstetrics*, **2013**, 287, 161-6	2.5	16
627	Effects of bipolar electrocoagulation versus suture after laparoscopic excision of ovarian endometrioma on the ovarian reserve and outcome of in vitro fertilization. **2013**, 39, 1246-52		29
626	Antimüllerian hormone as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study. *Fertility and Sterility*, **2013**, 100, 831-8	4.8	16
625	Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH. **2013**, 27, 390-9		52
624	Sexual and reproductive health in cancer survivors. **2013**, 40, 726-44		44
623	A contagem dos folículos antrais na predição de resultados em ciclos de fertilização in vitro: uma revisão sistemática. **2013**, 28, 68-73		2
622	Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. *Fertility and Sterility*, **2013**, 100, 420-9.e7	4.8	117
621	Assessment of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with familial Mediterranean fever. **2013**, 170, 449-51		4
620	Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization. **2013**, 168, 173-7		34
619	Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. *Fertility and Sterility*, **2013**, 100, 1270-6	4.8	52
618	Cancer and fertility preservation: Barcelona consensus meeting. **2013**, 29, 285-91		23
617	Tumor necrosis factor-308 polymorphism increases the embryo implantation rate in women undergoing in vitro fertilization. **2013**, 28, 2774-83		8

616	The success of assisted reproduction technologies in relation to composition of the total regulatory T cell (Treg) pool and different Treg subsets. **2013**, 28, 3062-73		23
615	Reduced quality and accelerated follicle loss with female reproductive aging - does decline in theca dehydroepiandrosterone (DHEA) underlie the problem?. **2013**, 20, 93		24
614	Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. **2013**, 98, 1107-14		100
613	Impact of high basal FSH/LH ratio in women with normal FSH levels on in vitro fertilization outcomes. **2013**, 29, 424-9		10
612	[Predictive models for ART]. **2013**, 42, 12-20		1
611	Impact of breast cancer on anti-mullerian hormone levels in young women. **2013**, 137, 571-7		39
610	Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. *Fertility and Sterility*, **2013**, 99, 1644-53	4.8	119
609	Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. **2013**, 49, 3404-11		90
608	Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates. *Fertility and Sterility*, **2013**, 99, 382-8	4.8	9
607	A common Asn680Ser polymorphism in the follicle-stimulating hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in patients undergoing in vitro fertilization. *Fertility and Sterility*, **2013**, 99, 149-155	4.8	29
606	High live birth rate in the subsequent IVF cycle after first-cycle poor response among women with mean age 35 and normal FSH. **2013**, 27, 362-6		7
605	IVF outcome in poor responders failing to produce viable embryos in the preceding cycle. **2013**, 26, 569-76		8
604	One-year follow-up of serum antimüllerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve?. *Fertility and Sterility*, **2013**, 100, 516-22.e3	4.8	80
603	Reproductive hormone concentrations in pregnancy and neonates: a systematic review. **2013**, 27, 33-63		112
602	Serum anti-Müllerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. **2013**, 7, e29-34		51
601	The impact of uterine artery embolization on ovarian function. **2013**, 24, 459-67		59
600	Biomarkers of ovarian response: current and future applications. *Fertility and Sterility*, **2013**, 99, 963-9	4.8	156
599	Prospective analysis of ovarian reserve markers as determinant in response to controlled ovarian stimulation in women undergoing IVF cycles in low resource setting in India. *Archives of Gynecology and Obstetrics*, **2013**, 288, 697-703	2.5	5

598	Ovarian endometrioma: guidelines for selection of cases for surgical treatment or expectant management. **2013**, 8, 29-55		2
597	The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). *Journal of Assisted Reproduction and Genetics*, **2013**, 30, 649-55	3.4	37
596	DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism. **2013**, 168, 49-53		30
595	Anti-Mllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome. **2013**, 29, 826-9		5
594	Infertility. **2013**, 251-270		3
593	Pregnancy prognosis in women with anti-Mllerian hormone below the tenth percentile. **2013**, 29, 662-5		10
592	High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol. **2013**, 28, 442-52		51
591	Predicting reproductive age with biomarkers of ovarian reserve--how (and what) are we measuring?. **2013**, 31, 416-26		12
590	Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction. **2013**, 2013, 383278		8
589	Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction. **2013**, 6, 27-31		20
588	Antral follicle count predicts natural menopause in a population-based sample: the Coronary Artery Risk Development in Young Adults Women's Study. **2013**, 20, 825-30		21
587	Role of surgery in endometriosis-associated subfertility. **2013**, 31, 133-43		37
586	Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. **2013**, 28, 2981-9		38
585	Benign ovarian cysts in reproductive-age women undergoing assisted reproductive technology treatment. **2013**, 03, 17-22		0
584	Fertility preservation options after gonadotoxic chemotherapy. **2013**, 7, 61-9		18
583	Biomarkers of ovarian reserve in women with polycystic ovary syndrome. **2013**, 31, 452-61		2
582	Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. *Human Reproduction Update*, **2013**, 19, 26-36	15.8	281
581	Biomarkers of ovarian reserve. **2013**, 7, 147-58		18

580   Diagnostic prîmplantatoire. **2013**, 8, 1-11

579   Effect of follicle-stimulating hormone receptor N680S polymorphism on the efficacy of follicle-stimulating hormone stimulation on donor ovarian response. **2013**, 23, 262-8   21

578   Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts. **2013**, 121, 71-7   60

577   Relative contribution of advanced age and reduced follicle pool size on reproductive success. 318-329   1

576   Premenopause: the endocrinology of reproductive decline. **2013**, 12, 334-49   7

575   Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. **2013**, 8, e61095   58

574   Ovarian volume throughout life: a validated normative model. **2013**, 8, e71465   60

573   Prediction of reproductive outcomes according to different serum anti-Mllerian hormone levels in females undergoing intracystoplasmic sperm injection. **2013**, 8, e75685   4

572   Endometriosis of the ovary. 189-198   1

571   Supplementation with estradiol valerate and gonadotropins in clomiphene citrate stimulated IUI cycles.. **2014**, 5, 211   3

570   Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study. **2014**, 9, e108493   16

569   Body mass index and pregnancy outcome after assisted reproduction treatment. **2014**, 2014, 257974   4

568   Management of poor responders in IVF: is there anything new?. **2014**, 2014, 352098   84

567   Fertility Preservation. **2014**, 791-821.e7   3

566   A proteomic analysis of human follicular fluid: comparison between younger and older women with normal FSH levels. **2014**, 15, 17518-40   27

565   Ultrasonography in Gynecology. 264-273   1

564   Ovarian aging and premature ovarian failure. **2014**, 15, 190-6   47

563   Preserving fertility in patients undergoing treatment for breast cancer: current perspectives. **2014**, 6, 93-101   2

| 562 | Número de folículos antrais e o sucesso da fertilização in vitro: uma análise multivariada. **2014**, 36, 473-479 | 3 |

| 561 | Informing patients about declining fertility. **2014**, 16, 787-92 | 1 |

| 560 | Ultrasound Imaging in Reproductive Medicine. **2014**, | 3 |

| 559 | ESR1 and ESR2 gene polymorphisms are associated with human reproduction outcomes in Brazilian women. **2014**, 7, 114 | 26 |

| 558 | Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review. **2014**, 12, 125 | 32 |

| 557 | Embryo quality in controlled ovarian stimulation for in vitro fertilization in young poor responders. **2014**, 30, 657-9 | 4 |

| 556 | A critical review of bi-dimensional and three-dimensional ultrasound techniques to monitor follicle growth: do they help improving IVF outcome?. **2014**, 12, 107 | 22 |

| 555 | Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis. **2014**, 30, 372-6 | 22 |

| 554 | Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers. **2014**, 30, 490-3 | 7 |

| 553 | Regular menstrual cycles do not rule out ovarian damage in adult women with systemic lupus erythematosus. **2014**, 30, 701-4 | 11 |

| 552 | Evaluation of granulocyte colony-stimulating factor effects on treatment-resistant thin endometrium in women undergoing in vitro fertilization. **2014**, 2014, 913235 | 64 |

| 551 | Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. **2014**, 29, 1688-97 | 41 |

| 550 | The Bologna criteria for poor ovarian response: the good, the bad and the way forward. **2014**, 29, 1839-41 | 33 |

| 549 | Hormônio anti-Mülleriano: cuidados na interpretaõ dos resultados. **2014**, 29, 1-2 | |

| 548 | Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation. **2014**, 10, 505-9 | 9 |

| 547 | Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol. **2014**, 4, e005767 | 8 |

| 546 | Implications of Blood Type for Ovarian Reserve and Infertility - Impact on Oocyte Yield in IVF Patients. **2014**, 74, 928-932 | 7 |

| 545 | Effect of ABO blood type on ovarian reserve in Chinese women. *Fertility and Sterility*, **2014**, 102, 1729-32.e2 | 13 |

544	Role of ultrasonographic markers of ovarian reserve in prediction of IVF and ICSI outcome. **2014**, 30, 290-3		5
543	Two-Dimensional and Three-Dimensional Doppler in Reproductive Medicine. **2014**, 27-39		
542	Ovarian reserve test: an impartial means to resolve the mismatch between chronological and biological age in the assessment of female reproductive chances. *Reproductive Sciences*, **2014**, 21, 632-9 [3]		28
541	FSHR gene polymorphisms affect the ovarian response to rFSH stimulation in Egyptian patients undergoing ARTs. **2014**, 13, 61-67		1
540	Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial. **2014**, 29, 1659-65		38
539	Assisted Reproduction. **2014**, 734-773.e12		1
538	Ala307Thr and Asn680Ser polymorphisms of FSHR gene in human reproduction outcomes. **2014**, 34, 1527-35		24
537	Reference range for the antimüllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram. *Fertility and Sterility*, **2014**, 101, 523-9	4.8	54
536	Predictive value of androgens and multivariate model for poor ovarian response. **2014**, 28, 723-32		10
535	AMH concentration is not related to effective time to pregnancy in women who conceive naturally. **2014**, 28, 216-24		42
534	Elevated day 3 follicle-stimulating hormone in younger women: is gonadotropin stimulation/intrauterine insemination a good option?. **2014**, 211, 62.e1-8		5
533	The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. *Fertility and Sterility*, **2014**, 101, 427-34	4.8	96
532	The root of reduced fertility in aged women and possible therapentic options: current status and future perspects. **2014**, 38, 54-85		81
531	Hormonal and functional biomarkers in ovarian response. *Archives of Gynecology and Obstetrics*, **2014**, 289, 1355-61	2.5	19
530	Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. *Fertility and Sterility*, **2014**, 101, 147-53	4.8	69
529	Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 493-8	3.4	34
528	Quality of embryos transferred and progesterone levels are the most important predictors of live birth after fresh embryo transfer: a retrospective cohort study. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 185-94	3.4	19
527	Low testosterone levels in women with diminished ovarian reserve impair embryo implantation rate: a retrospective case-control study. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 485-91	3.4	20

526	Low dose of rFSH [100 IU] in controlled ovarian hyperstimulation response: a pilot study. **2014**, 7, 11		10
525	Female age-related fertility decline. Committee Opinion No. 589. *Fertility and Sterility*, **2014**, 101, 633-4	4.8	227
524	Effects of dehydroepiandrosterone on in vivo ovine follicular development. **2014**, 29, 146-54		39
523	Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies. **2014**, 29, 1218-24		53
522	Change in oocyte yield in repeated in vitro fertilization cycles: effect of ovarian reserve. *Fertility and Sterility*, **2014**, 101, 399-402	4.8	12
521	Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. *Human Reproduction Update*, **2014**, 20, 124-40	15.8	295
520	Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. *Fertility and Sterility*, **2014**, 102, 1633-40.e5	4.8	109
519	Fertility preservation in women with cancer. **2014**, 384, 1302-10		229
518	The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link?. **2014**, 90, 85		118
517	Medical Approaches to Ovarian Stimulation for Infertility. **2014**, 701-733.e8		1
516	Basal serum anti-mllerian hormone and antral follicle count are predictors of ovarian response for Asian women in Singapore. **2014**, 3, 169-175		3
515	Targeted anti-apoptosis activity for ovarian protection against chemotherapy-induced ovarian gonadotoxicity. **2014**, 29, 612-20		17
514	Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Mllerian hormone (AMH) levels and histological analysis. **2014**, 181, 205-9		14
513	AMH: An ovarian reserve biomarker in assisted reproduction. **2014**, 437, 175-82		46
512	Androgen receptor CAG repeat length is associated with ovarian reserve but not with ovarian response. **2014**, 29, 509-15		5
511	Evaluation of the ovarian reserve function in patients with metabolic syndrome in relation to healthy controls and different age groups. **2014**, 7, 63		7
510	Basal serum testosterone levels correlate with ovarian response but do not predict pregnancy outcome in non-PCOS women undergoing IVF. *Journal of Assisted Reproduction and Genetics*, **2014**, 31, 829-35	3.4	15
509	Assessment of ovarian reserve after unilateral diathermy with thermal doses adjusted to ovarian volume. **2014**, 30, 785-8		8

508   Endometriosis. **2014**,   4

507   The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. *Human Reproduction Update*, **2014**, 20, 560-70   15.8   154

506   Evaluation of ovarian reserve tests in women with systemic lupus erythematosus. **2014**, 72, 85-8   12

505   Argon beam coagulator versus cystectomy for endometrioma treatment in infertile women and the impact on ovarian reserve. A case control study. **2014**, 19, 22-26   1

504   Impact on ovarian reserve after laparoscopic ovarian cystectomy with reduced port number: a randomized controlled trial. **2014**, 176, 34-8   17

503   Comparability of antimüllerian hormone levels among commercially available immunoassays. *Fertility and Sterility*, **2014**, 101, 1766-72.e1   4.8   46

502   Can Doppler study of the ovarian artery predict the fertility outcome of intrauterine insemination?. **2014**, 42, 331-5   3

501   Ultrasonography in Gynecology. 233-237

500   Premature ovarian failure. 119-128

499   Female age-related fertility decline. Committee Opinion No. 589. **2014**, 123, 719-721   73

498   Prenatal diethylstilbestrol exposure and reproductive hormones in premenopausal women. **2015**, 6, 208-16   10

497   Is Anti-Müllerian Hormone Associated With Fecundability? Findings From the EAGeR Trial. **2015**, 100, 4215-21   54

496   Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles. **2015**, 13, 117   18

495   Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 1441-8   3.4   14

494   Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049). **2015**, 83, 902-12   9

493   The impact of previous ovarian surgery on ovarian reserve in patients with endometriosis. **2015**, 15, 74   10

492   The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data. **2015**, 13, 134   34

491   Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring. **2015**, 12, 113   4

490 The Bologna criteria for poor ovarian response: a contemporary critical appraisal. **2015**, 8, 76   57

489 Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. **2015**, 8, 82   17

488 Effects of transcutaneous electrical acupoint stimulation on ovarian reserve of patients with diminished ovarian reserve in in vitro fertilization and embryo transfer cycles. **2015**, 41, 1905-11   18

487 Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction. **2015**, 94, 1056-63   30

486 Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. **2015**, 126, 187-95   81

485 Ovarian response biomarkers: physiology and performance. **2015**, 27, 182-6   28

484 Predictive Value of AMH, FSH and AFC for Determining Ovarian Response in Vietnamese Women Undergoing Assisted Reproductive Technologies: A Prospective Study. **2015**, 03,

483 Ovarian reserve markers in unexplained infertility patients treated with clomiphene citrate during intrauterine insemination. **2015**, 11, 1250-4   5

482 Effect of early endometriosis on ovarian reserve and reproductive outcome. **2015**, 7, 40-5   1

481 Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice. **2015**, 7, 69-76   5

480 Utilidad de la determinación de la reserva ovárica como predictor de la posibilidad de embarazo espontáneo: Revisión sistemática. **2015**, 80, 421-425

479 Genetics of the ovarian reserve. **2015**, 6, 308   39

478 Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. **2015**, 8, 3349-59   31

477 Serum dehydroepiandrosterone sulphate concentration is not a predictive factor in IVF outcomes before the first cycle of GnRH agonist administration in women with normal ovarian reserve. **2015**, 10, e0118570   3

476 Live birth and cumulative live birth rates in expected poor ovarian responders defined by the Bologna criteria following IVF/ICSI treatment. **2015**, 10, e0119149   14

475 Lights and Shadows about the Effectiveness of IVF in HIV Infected Women: A Systematic Review. **2015**, 2015, 517208   8

474 Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas. *Fertility and Sterility*, **2015**, 103, 1544-50.e1-3   4.8   15

473 Potential Etiologies of Unexplained Infertility in Females. **2015**, 141-147   3

472	Is ABO blood type associated with ovarian stimulation response in patients with diminished ovarian reserve?. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 985-90	3.4	8
471	Prediction of different ovarian responses using anti-Müllerian hormone following a long agonist treatment protocol for IVF. **2015**, 38, 1007-15		16
470	Obesity and Fertility. **2015**,		1
469	Committee opinion no. 618: Ovarian reserve testing. **2015**, 125, 268-273		79
468	Comparison between the stripping technique and the combined excisional/ablative technique for the treatment of bilateral ovarian endometriomas: a multicentre RCT. **2016**, 31, 339-44		24
467	Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians. **2016**, 31, 403-11		57
466	Which set of embryo variables is most predictive for live birth? A prospective study in 6252 single embryo transfers to construct an embryo score for the ranking and selection of embryos. **2015**, 30, 28-36		43
465	Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. *Human Reproduction Update*, **2015**, 21, 698-710	15.8	131
464	Counseling and diagnostic evaluation for the infertile couple. **2015**, 42, 1-14		7
463	The effect of isotretinoin on ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with acne. **2015**, 79, 78-82		12
462	Anti-Müllerian Hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. **2015**, 80, 251-7		22
461	Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertility and Sterility*, **2015**, 103, e9-e17	4.8	213
460	Poor responders in IVF: an update in therapy. **2015**, 31, 253-7		16
459	Anti-mullerian hormone concentration during the third trimester of pregnancy and puerperium: a longitudinal case-control study in normal and diabetic pregnancy. *Endocrine*, **2015**, 50, 250-5	4	9
458	Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. *Reproductive Sciences*, **2015**, 22, 519-26	3	32
457	Blood type predicts live birth in the infertile population. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 551-5	3.4	4
456	What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?. **2015**, 13, 58		12
455	Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. *Fertility and Sterility*, **2015**, 104, 1016-1021.e6	4.8	74

| 454 | Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol. *Fertility and Sterility*, **2015**, 104, 884-890.e2 | 4.8 | 19 |

| 453 | Clinical Assessment of Ovarian Toxicity. **2015**, 35-45 | | |

| 452 | Ovarian response is affected by a specific histidine-rich glycoprotein polymorphism: a preliminary study. **2015**, 30, 74-81 | | 10 |

| 451 | Premature Menopause. **2015**, 44, 543-57 | | 24 |

| 450 | Protective effect of resveratrol against oxidative damage to ovarian reserve in female Sprague-Dawley rats. **2015**, 31, 404-10 | | 29 |

| 449 | Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. **2015**, 31, 347-55 | | 8 |

| 448 | Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study. **2015**, 30, 1974-81 | | 29 |

| 447 | Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. *Fertility and Sterility*, **2015**, 104, 612-19.e3 | 4.8 | 74 |

| 446 | Diagnostic evaluation of the infertile female: a committee opinion. *Fertility and Sterility*, **2015**, 103, e44-50 | 4.8 | 184 |

| 445 | [Gonadal function after treatment for a childhood or adolescent cancer]. **2015**, 102, 602-11 | | 3 |

| 444 | Effect on ovarian reserve of hemostasis by bipolar coagulation versus suture during laparoendoscopic single-site cystectomy for ovarian endometriomas. **2015**, 22, 415-20 | | 25 |

| 443 | Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART. **2015**, 13, 28 | | 21 |

| 442 | OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. **2015**, 8, 21 | | 18 |

| 441 | How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. **2015**, 30, 581-92 | | 70 |

| 440 | Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. *Fertility and Sterility*, **2015**, 103, 923-930.e1 | 4.8 | 84 |

| 439 | Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. *Fertility and Sterility*, **2015**, 103, 1074-1080.e4 | 4.8 | 54 |

| 438 | Exploring the relationship between endometriomas and infertility. **2015**, 11, 127-35 | | 7 |

| 437 | Follicular fluid anti-Müllerian hormone: a predictive marker of fertilization capacity of MII oocytes. *Archives of Gynecology and Obstetrics*, **2015**, 291, 681-7 | 2.5 | 6 |

436   Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. **2015**, 21-31

435   Principles and Practice of Controlled Ovarian Stimulation in ART. **2015**,   2

434   Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM). **2015**, 100, 2597-605   3

433   AMH and AMHR2 polymorphisms and AMH serum level can predict assisted reproduction outcomes: a cross-sectional study. **2015**, 35, 1401-12   25

432   The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation. **2015**, 82, 577-83   24

431   Anti-Müllerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review. **2015**, 55, 363-367

430   Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions. *Journal of Assisted Reproduction and Genetics*, **2015**, 32, 1709-12   3.4   87

429   Associations Between Antral Ovarian Follicle Dynamics and Hormone Production Throughout the Menstrual Cycle as Women Age. **2015**, 100, 4553-62   18

428   Evaluation of the effects of fulvestrant and micronized progesterone on the post-operative adhesion formation and ovarian reserve in rat model with immunohistochemical and biochemical analysis. **2015**, 31, 667-72   2

427   Niveles sŕicos de hormona antimulleriana como predictor de baja respuesta en mujeres sometidas a ciclos de fecundaciŕ in vitro. **2015**, 2, 9-16   1

426   Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. **2015**, 31, 486-96   135

425   Screening the Single Euploid Embryo. **2015**,

424   [Anti-Müllerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review]. **2015**, 55, 363-7   4

423   Anti-Müllerian hormone as a possible predictor of fecundability in subfertile women over 38 years: a retrospective cohort study. **2015**, 31, 22-5   7

422   Relationship between circulating anti-Müllerian hormone (AMH) and superovulatory response of high-producing dairy cows. **2015**, 98, 169-78   53

421   [Impact of serum Anti-Mullerian Hormone levels on the results of assisted reproductive technologies. Single-center retrospective study from 2011 cycles (ICSI and bilateral tubal obstruction excluded)]. **2015**, 44, 63-71   3

420   Evaluation of ovarian reserve and function in female patients treated with oral isotretinoin for severe acne: an exploratory study. **2015**, 34, 21-4   12

419   Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone. **2015**, 30, 170-8   38

418	Endometrioma is a Responsible Factor for Reduced Ovarian Reserve. **2016**, 30, 98-104		
417	Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation. **2016**, 43, 112-8		15
416	The relationship between antral follicle count in a bovine ovary and developmental competence of in vitro-grown oocytes derived from early antral follicles. **2016**, 37, 63-71		12
415	Long-Term Moderate Oxidative Stress Decreased Ovarian Reproductive Function by Reducing Follicle Quality and Progesterone Production. **2016**, 11, e0162194		34
414	Clinical efficacy of recombinant versus highly purified follicle-stimulating hormone according to follicle-stimulating hormone receptor genotype. **2016**, 26, 288-93		5
413	Recuento de folïulos antrales como predictor de la respuesta ovɓïca. **2016**, 80, 252-257		1
412	Effect of growth differentiation factor-9 ́C447T and G546A polymorphisms on the outcomes of in ́vitro fertilization. **2016**, 13, 4437-42		5
411	Involvement of mesosalpinx in endometrioma is a possible risk factor for decrease of ovarian reserve after cystectomy: a retrospective cohort study. **2016**, 14, 72		7
410	The Effects of Diabetes Mellitus on Ovarian Injury and Reserve: An Experimental Study. **2016**, 81, 424-9		11
409	Ethnicity or environment: effects of migration on ovarian reserve among Bangladeshi women in the United Kingdom. *Fertility and Sterility*, **2016**, 105, 744-754.e1	4.8	26
408	Variation in antral follicle counts at different times in the menstrual cycle: does it matter?. **2016**, 33, 174-9		8
407	Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art. **2016**, 12, 1731-41		6
406	Fertility in midlife women. **2016**, 19, 240-6		9
405	Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation. *Fertility and Sterility*, **2016**, 105, 690-696	4.8	9
404	Antimɬerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial. *Fertility and Sterility*, **2016**, 105, 946-952.e2	4.8	19
403	Cancer and Fertility. **2016**,		1
402	Gonadotrophin-releasing hormone agonist protocol of controlled ovarian hyperstimulation as an efficient treatment in Bologna-defined poor ovarian responders. **2016**, 62, 290-6		6
401	Individualized follicle-stimulating hormone dosing and in ́vitro fertilization outcome in agonist downregulated cycles: a systematic review. **2016**, 95, 1333-1344		9

382	The influence of AMH on IVF success. *Archives of Gynecology and Obstetrics*, **2016**, 293, 667-73	2.5	31
381	Low level of basal testosterone: a significant risk factor for poor oocyte yield after ovulation induction. **2016**, 28, 286-92		1
380	Value of in situ ovarian volume measured during cesarean delivery to assess the potential of diminished ovarian reserve. **2017**, 30, 1016-1022		2
379	Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women: Results From the Doetinchem Cohort Study. **2017**, 135, 556-565		30
378	Ovarian reserve testing: a user's guide. **2017**, 217, 129-140		164
377	The effect of G-CSF on infertile women undergoing IVF treatment: A meta-analysis. **2017**, 63, 239-247		27
376	Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study. **2017**, 39, 162-168		5
375	Preimplantation genetic diagnosis for aneuploidy testing in women older than 44 years: a multicenter experience. *Fertility and Sterility*, **2017**, 107, 1173-1180	4.8	49
374	Surgery versus conservative management of endometriomas in subfertile women. A systematic review. **2017**, 96, 727-735		21
373	Age is a major prognosticator in extremely low oocyte retrieval cycles. **2017**, 56, 175-180		5
372	Opportunistic Salpingectomy Does Not Affect Ovarian Reserve or Surgical Outcomes in Patients Undergoing Laparoscopic Myomectomy. **2017**, 82, 468-474		1
371	Development of In Vitro Maturation for Human Oocytes. **2017**,		2
370	Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. **2017**, 35, 3-16		16
369	Ovarian reserve after salpingectomy: a systematic review and meta-analysis. **2017**, 96, 795-803		29
368	Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. **2017**, 79, 72-80		43
367	Ovarian reserve after fibroid embolization in premenopausal women. **2017**, 26, 284-291		11
366	The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial. **2017**, 32, 811-819		24
365	Anti-Müllerian Hormone (AMH) and fertility management in agricultural species. **2017**, 154, R1-R11		41

346	Managing Ultrasonography in Human Reproduction. **2017**,	1
345	Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. **2017**, 32, 2485-2495	48
344	Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. **2017**, 32, 2506-2514	48
343	[Association between antral follicle count and age in fertile women]. **2017**, 145, 741-746	0
342	Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology. **2017**, 2017, 9451235	5
341	Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back. **2017**, 3, 15	29
340	The effect of DHEA on apoptosis and cohesin levels in oocytes in aged mice. **2017**, 11, 427-438	4
339	How to personalize ovarian stimulation in clinical practice. **2017**, 18, 148-153	9
338	Feature of amenorrhea in postoperative tamoxifen users with breast cancer. **2017**, 28, e10	5
337	Female Infertility (AMH and FSH) over the Age of 35 in the Dukagjini Region in the Republic of Kosovo. **2017**, 06,	
336	Freeze-all embryo strategy in poor ovarian responders undergoing ovarian stimulation for in vitro fertilization. **2018**, 34, 680-683	9
335	Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: A cross sectional study. **2018**, 222, 119-125	8
334	Clinical application of serum anti-Mllerian hormone as an ovarian reserve marker: A review of recent studies. **2018**, 44, 998-1006	21
333	What is new in the management of poor ovarian response in IVF?. **2018**, 30, 155-162	49
332	Persistent organic pollutants as predictors of increased FSH:LH ratio in naturally cycling, reproductive age women. **2018**, 164, 556-564	16
331	Very low anti-mllerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. **2018**, 37, 113-119	11
330	Poor ovarian response as a predictor for live birth in older women undergoing IVF. **2018**, 36, 435-441	12
329	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). **2018**, 2, CD012693	48

328	Age-specific reference values and cut-off points for anti-mūlerian hormone in infertile women following a long agonist treatment protocol for IVF. **2018**, 41, 773-780		4
327	CGG repeat length and AGG interruptions as indicators of fragile X-associated diminished ovarian reserve. **2018**, 20, 957-964		14
326	Ovarian function, fertility and reproductive lifespan in cancer patients. **2018**, 13, 125-136		32
325	Does ovarian reserve affect outcomes in single ideal blastocyst transfers in women less than 40´years of age?. *Archives of Gynecology and Obstetrics*, **2018**, 297, 233-239	2.5	4
324	Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. *Journal of Assisted Reproduction and Genetics*, **2018**, 35, 17-23	3.4	48
323	Anti-Mūlerian Hormone: genetic and environmental effects. **2018**, 476, 123-129		18
322	Laparoscopic Excision Ablation or Ablation Alone in Women with Endometrioma. **2018**, 04,		
321	Prognosticating ovarian reserve by the new ovarian response prediction index. **2018**, 7, 1196		
320	Ovarian Reserve Markers: An Update. **2018**,		
319	Association of progesterone production with serum anti-Mūlerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa. **2018**, 13, e0206111		1
318	Declining Fertility with Reproductive Aging: How to Protect Your Patient's Fertility by Knowing the Milestones. **2018**, 45, 575-583		2
317	Radiations and female fertility. **2018**, 16, 112		22
316	Demographic characteristics and AMH levels in rural and urban women participating in an IVF programme. **2018**, 25, 120-123		0
315	Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice. **2018**, 10, 1089-1102		7
314	Factors affecting the live-birth rate in women with diminished ovarian reserve undergoing IVF-ET. *Archives of Gynecology and Obstetrics*, **2018**, 298, 1017-1027	2.5	13
313	Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve. *Archives of Gynecology and Obstetrics*, **2018**, 298, 1029-1035	2.5	45
312	The dilemma of social oocyte freezing: usage rate is too low to make it cost-effective. **2018**, 37, 443-448		14
311	Basal Serum Anti-Mūlerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program. **2018**, 38, 861-867		4

| 310 | Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study. **2018**, 28, 1702-1707 | 22 |

| 309 | Haemoglobinopathy: considerations for reproductive health. **2018**, 20, 253-259 | 0 |

| 308 | Methods of evaluation of the ovarian reserve. **2018**, 1, 62-66 | |

| 307 | Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type. **2018**, 37, 201-207 | 13 |

| 306 | Histomorphological Aspects of the Ovarian Cortex Regarding Ovarian Reserve and Local Pelvic Inflammation. **2018**, 35, 21-26 | 2 |

| 305 | A Review of Infertility for the Primary Care Provider. **2018**, 3, 423-432 | |

| 304 | Is the ovarian reserve influenced by vitamin D deficiency and the dress code in an infertile Iranian population?. **2018**, 11, 62 | 12 |

| 303 | Nanosized titanium dioxide-induced premature ovarian failure is associated with abnormalities in serum parameters in female mice. **2018**, 13, 2543-2549 | 13 |

| 302 | Forty years of IVF. *Fertility and Sterility*, **2018**, 110, 185-324.e5 | 4.8 | 108 |

| 301 | Discordant anti-mªlerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth?. **2018**, 11, 60 | 20 |

| 300 | Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF. **2018**, 33, 1499-1505 | 11 |

| 299 | The deferred embryo transfer strategy improves cumulative pregnancy rates in endometriosis-related infertility: A retrospective matched cohort study. **2018**, 13, e0194800 | 27 |

| 298 | Bilan avant assistance mªdicale ˆla procrªtion : le versant fªminin. **2018**, 2018, 36-42 | |

| 297 | Successful spontaneous pregnancy with acupuncture after premature ovarian failure. **2018**, 28, 137-140 | 0 |

| 296 | The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation. **2018**, 9, 361 | 26 |

| 295 | Relationship between the antral follicle count in bovine ovaries from a local abattoir and steroidogenesis of granulosa cells cultured as oocyte-cumulus-granulosa complexes. **2018**, 64, 503-510 | 5 |

| 294 | Reproductive aging and elective fertility preservation. **2018**, 11, 66 | 29 |

| 293 | Endometriosis and ART: A prior history of surgery for OMA is associated with a poor ovarian response to hyperstimulation. **2018**, 13, e0202399 | 13 |

274	Relationships between the antral follicle count, steroidogenesis, and secretion of follicle-stimulating hormone and anti-Müllerian hormone during follicular growth in cattle. **2019**, 17, 88		12
273	Does different subfertility etiology affect pregnancy rates in intrauterineinsemination cycles?. **2019**, 49, 1439-1443		
272	Weight management merits attention in women with infertility: a cross-sectional study on the association of anthropometric indices with hormonal imbalance in a Ghanaian population. **2019**, 12, 545		0
271	Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer. **2019**, 39, 712-720		4
270	Antral follicle responsiveness assessed by follicular output RaTe(FORT) correlates with follicles diameter. **2019**, 12, 48		7
269	Do young women with unexplained infertility show manifestations of decreased ovarian reserve?. *Journal of Assisted Reproduction and Genetics*, **2019**, 36, 1143-1152	3.4	6
268	Low antimüllerian hormone (AMH) is associated with decreased live birth after in´vitro fertilization when follicle-stimulating hormone and AMH are discordant. *Fertility and Sterility*, **2019**, 112, 73-81.e1	4.8	11
267	In Vitro Activation Following Ovarian Tissue Cryopreservation: A Case of Patient with POI. **2019**, 463-466		
266	Do serum androgens influence blastocysts ploidy in karyotypically normal women?. **2019**, 65, 281-287		
265	Assessment of ovarian reserve using serum anti-Müllerian hormone after ovarian torsion surgery. **2019**, 61, 504-507		6
264	A predictive formula for selecting individual FSH starting dose based on ovarian reserve markers in IVF/ICSI cycles. *Archives of Gynecology and Obstetrics*, **2019**, 300, 441-446	2.5	3
263	Assessment of Ovarian Reserve. **2019**, 36-48		
262	Ovarian reserve in an Egyptian cohort with end-stage kidney disease on hemodialysis and after successful kidney transplantation: a prospective study. **2019**, 51, 737-743		4
261	Does the anti-Müllerian hormone truly reflect ovarian response in women with endometrioma?. **2019**, 39, 516-521		4
260	Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation. **2019**, 34, 2513-2522		16
259	Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. *Journal of Assisted Reproduction and Genetics*, **2019**, 36, 2485-2491	3.4	4
258	Infertility Workup for the Women's Health Specialist: ACOG Committee Opinion, Number 781. **2019**, 133, e377-e384		70
257	The relevance of the individual screening for genetic variants in predicting ovarian response. **2019**, 29, 216-223		2

256   Ovaires et fertilit'en 2019´: pr̆servation de la fertilit̂, r̆serve ovarienne, ovaires polykystiques. **2019**, 29, 99-104

255   From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology. **2019**, 35, 184-189   4

254   Elevation of antimⵐlerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. *Fertility and Sterility*, **2019**, 111, 157-167   4.8   13

253   Pre-Clinical Models. **2019**,   6

252   Assaying Reproductive Capacity in Female Rodents. **2019**, 1916, 157-166

251   The Role of Antimullerian Hormone in Assisted Reproduction. **2019**, 403-414

250   Investigation of the preventive effects of dehydroepiandrosterone (DHEA) and Caffeic acid phenethyl ester (CAPE) on cisplatin-induced ovarian damage in rats. **2020**, 44, 71-80   1

249   Real-world effectiveness of Fertistartkitⵐ treatment in women undergoing ART in French clinical practice: a retrospective multicentre study. **2020**, 40, 525-529

248   Follicular fluid steroid profile in sows: relationship to follicle size and oocyte qualityⵐ **2020**, 102, 740-749   6

247   The Relationship Between Serum Delta FSH Level and Ovarian Response in IVF/ICSI Cycles. **2020**, 11, 536100   1

246   AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles. **2020**, 10, 19750   9

245   The effect of adenomyosis on IVF after long or ultra-long GnRH agonist treatment. **2020**, 41, 845-853   9

244   Women with a substance use disorder: Treatment completion, pregnancy, and compulsory treatment. **2020**, 116, 108045   1

243   Role of 3-D Transvaginal Ultrasonography in Women Undergoing in Vitro Fertilization/Intra-cytoplasmic Sperm Injection. **2020**, 46, 1424-1427   1

242   Early ovarian ageing: is a low number of oocytes harvested in young women associated with an earlier and increased risk of age-related diseases?. **2020**, 35, 2375-2390   6

241   D-Chiro-Inositol Treatment Affects Oocyte and Embryo Quality and Improves Glucose Intolerance in Both Aged Mice and Mouse Models of Polycystic Ovarian Syndrome. **2020**, 21,   4

240   Clinical Application of AMH Measurement in Assisted Reproduction. **2020**, 11, 606744   2

239   ESHRE guideline: ovarian stimulation for IVF/ICSI. **2020**, 2020, hoaa009   66

238	Preservation of fertility in patients with hematological malignancies. **2020**, 50, 729-742		2
237	Is there a difference in ovarian reserve biomarkers and ovarian response between the right and left ovaries?. **2020**, 41, 416-424		2
236	Management Strategies for POSEIDON Group 2. **2020**, 11, 105		5
235	Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment. **2020**, 35, 504-515		8
234	Diminished ovarian reserve in recurrent pregnancy loss: a systematic review and meta-analysis. *Fertility and Sterility*, **2020**, 113, 818-827.e3	4.8	17
233	Perinatal outcome in young patients with diminished ovarian reserve undergoing assisted reproductive technology. *Fertility and Sterility*, **2020**, 114, 118-124.e1	4.8	8
232	Comparative study of assisted reproductive outcomes between young patients with occult premature ovarian insufficiency and advanced-age patients. **2020**, 48, 300060520934656		0
231	The Ovarian Sensitivity Index (OSI) Significantly Correlates with Ovarian Reserve Biomarkers, Is More Predictive of Clinical Pregnancy than the Total Number of Oocytes, and Is Consistent in Consecutive IVF Cycles. *Journal of Clinical Medicine*, **2020**, 9,	5.1	4
230	Association of exposure to air pollution and green space with ovarian reserve hormones levels. **2020**, 184, 109342		12
229	Role of Ultrasound in Assisted Reproductive Treatment. **2020**, 145-167		
228	High-resolution H-NMR spectroscopy indicates variations in metabolomics profile of follicular fluid from women with advanced maternal age. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 321-330	3.4	4
227	Relationship between the timing of the first postpartum ovulation and antral follicle counts in Holstein cows. **2020**, 13, 7		0
226	A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 963-972	3.4	5
225	Epigenetic clock measuring age acceleration via DNA methylation levels in blood is associated with decreased oocyte yield. *Journal of Assisted Reproduction and Genetics*, **2020**, 37, 1097-1103	3.4	7
224	Age effect on in vitro fertilization pregnancy mediated by anti-Mullerian hormone (AMH) and modified by follicle stimulating hormone (FSH). **2020**, 20, 209		2
223	High incidence of diminished ovarian reserve in young unexplained recurrent pregnancy loss patients. **2020**, 36, 1079-1081		5
222	How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus. **2021**, 37, 255-263		3
221	Are ovarian reserve tests reliable in predicting ovarian response? Results from a prospective, cross-sectional, single-center analysis. **2021**, 37, 358-366		15

220	Assisted conception in women of advanced maternal age. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2021**, 70, 10-20	4.6	3
219	Guidelines informing counseling on female age-related fertility decline: a systematic review. *Journal of Assisted Reproduction and Genetics*, **2021**, 38, 41-53	3.4	2
218	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. **2021**, 3, 100293		6
217	Maternal age affects the relationship of basal FSH and anti-Müllerian hormone concentrations with post-ICSI/IVF live birth. **2021**, 42, 748-756		2
216	Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature. *Reproductive Sciences*, **2021**, 28, 495-509		3
215	How does pathology influence cumulative pregnancy rate in poor responder patients?. **2021**, 1, 23		
214	Effect of Female Age on Infertility Diagnostic Factors and In-vitro Fertilization Treatment Outcomes: A Single-center Retrospective Cohort Study.		
213	In-Vitro Fertilization Outcome Predictors in Women With High Baseline Follicle-Stimulating Hormone Levels: Analysis of Over 1000 Cycles From A Tertiary Center. **2021**, 25, 235-241		0
212	High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment. **2021**, 25, 266-271		0
211	Use of Anti-Mullerian Hormone (AMH) for Testing of Ovarian Reserve: A Survey of Fifteen (15) Fertility Centres in Ghana. **2021**, 09, 81-96		0
210	Anti-Mullerian hormone in systemic lupus erythematosus. **2021**, 15, 105-110		
209	An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review. *Journal of Assisted Reproduction and Genetics*, **2021**, 38, 2007-2020	3.4	1
208	Physiology of the Female Reproductive System. **2021**, 28-55		0
207	Individualized Ovarian Stimulation for Normal and High Responders. **2021**, 1-13		
206	The promised land of individualized ovarian stimulation: Are we there yet?. *Fertility and Sterility*, **2021**, 115, 893-894	4.8	1
205	Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. **2021**, 36, 1530-1541		3
204	Predictive Factors for Live Birth in Fresh Fertilization/Intracytoplasmic Sperm Injection Treatment in Poor Ovarian Reserve Patients Classified by the POSEIDON Criteria. **2021**, 12, 630832		0
203	Anti-Müllerian hormone as a predictor of pregnancy in women under 35 years with unexplained infertility undergoing ICSI: a retrospective study. **2021**,		

| 202 | Predictive value of anti-Müllerian hormone on pregnancy outcomes in in-vitro fertilization/intracytoplasmic single sperm injection patients at different ages. *Archives of Gynecology and Obstetrics*, **2021**, 304, 1611-1620 | 2.5 | 0 |

| 201 | High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients. **2021**, 12, 673284 | 0 |

| 200 | İntrasitoplazmik sperm enjeksiyonu (ICSI) uygulanan infertil kadınlarda gebelik başarısını etkileyen faktörlerin değerlendirilmesi. | |

| 199 | Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. **2021**, 225, 515.e1-515.e10 | 2 |

| 198 | Assistierte Fertilisation. **2021**, 23, 40-50 | |

| 197 | Association of exposure to ambient air pollution with ovarian reserve among women in Shanxi province of north China. **2021**, 278, 116868 | 0 |

| 196 | Does Adenomyosis Influence ICSI Clinical Outcome? A Systematic Analysis and Impact of GnRH Agonist Pretreatment for Women with Adenomyosis in ICSI-ET Cycle: A Retrospective Cohort Study. 1 | 1 |

| 195 | Urinary vitamin D-binding protein as a marker of ovarian reserve. **2021**, 19, 80 | 1 |

| 194 | The Effects of Endometriosis on Ovarian Functions. **2021**, 2, 142-149 | 0 |

| 193 | A Nuclear and Cytoplasmic Characterization of Bovine Oocytes Reveals That Cysteamine Partially Rescues the Embryo Development in a Model of Low Ovarian Reserve. **2021**, 11, | 1 |

| 192 | Association of bioavailable inhibin B and oocyte yield in controlled ovarian stimulation. **2021**, 2, 189-194 | 0 |

| 191 | Establishment of a homogeneous immunoassay-light-initiated chemiluminescence assay for detecting anti-Müllerian hormone in human serum. **2021**, 494, 113059 | 1 |

| 190 | Anti-Mullerian hormone (AMH) test information on Australian and New Zealand fertility clinic websites: a content analysis. **2021**, 11, e046927 | |

| 189 | The Association Between Long Working Hours and Infertility.. **2021**, 12, 517-521 | 1 |

| 188 | Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. **2021**, 22, | 7 |

| 187 | Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. **2021**, 152, 193-203 | 2 |

| 186 | Urinary Bisphenol A Concentrations and Parameters of Ovarian Reserve among Women from a Fertility Clinic. **2021**, 18, | 4 |

| 185 | Supernumerary embryos, do they show the cycle success in a fresh embryo transfer? A retrospective analysis. **2021**, 37, 1107-1110 | 0 |

184	Nomogram of age-specific anti-Müllerian hormone levels in healthy Egyptian females. **2021**, 16, e0254858	0
183	Prediction of pregnancy outcome in fresh fertilization/intracytoplasmic sperm injection treatment in patients with poor ovarian reserve. **2021**, 13, 18331-18339	0
182	Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. **2021**, 11,	1
181	Correlations among anti-Müllerian hormone levels, body mass index and lipid profile in reproductive-aged women: The Korea Nurses' Health Study. **2021**, 8, 2996-3005	1
180	Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients. **2021**, 12, 702061	1
179	The Influence of Cesarean Delivery on Ovarian Reserve: a Prospective Cohort Study. *Reproductive Sciences*, **2021**, 1	3
178	Role of AMH in Prediction of Menopause. **2021**, 12, 733731	2
177	Infertility and subsequent recurrent miscarriage: Current state of the literature and future considerations for practice and research. 4, 100	0
176	The Optimal Time of Ovarian Reserve Recovery After Laparoscopic Unilateral Ovarian Non-Endometriotic Cystectomy. **2021**, 12, 671225	1
175	The Exploration of Poor Ovarian Response-Related Risk Factors: A Potential Role of Growth Differentiation Factor 8 in Predicting Ovarian Response in IVF-ET Patient. **2021**, 12, 708089	0
174	Cholesterol metabolism is decreased in patients with diminished ovarian reserve. **2021**,	0
173	Persistent organic pollutants and the size of ovarian reserve in reproductive-aged women. **2021**, 155, 106589	7
172	Ultrasound and PCOS. **2014**, 75-91	1
171	General aspects of fertility and infertility. **2014**, 1154, 3-23	4
170	Assisted reproductive techniques. **2014**, 1154, 171-231	56
169	Female Age and Reproductive Chances. **2018**, 1-10	2
168	Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. **2020**, 134, 34-40	7
167	Egg Quality and Pregnancy Outcome in Young Infertile Women with Diminished Ovarian Reserve. **2018**, 24, 7279-7284	23

| 166 | Effect of obesity on ovarian reserve parameters in mid-reproductive age women. 1, 43 | 2 |

| 165 | Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles. **2013**, 8, e81629 | 27 |

| 164 | Effect of Genital Tuberculosis on Ovarian Reserve. **2020**, 16, 104 | 1 |

| 163 | Age as A Predictor of Embryo Quality Regardless of The Quantitative Ovarian Response. **2017**, 11, 40-46 | 17 |

| 162 | Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. **2019**, 61, 68-75 | 14 |

| 161 | Effect of adding human chorionic gonadotropin to frozen thawed embryo transfer cycles with history of thin endometrium. **2016**, 14, 53-56 | 6 |

| 160 | Efficacy of Intrauterine infusion of granulocyte colony stimulating factor on patients with history of implantation failure: A randomized control trial. **2016**, 14, 687-690 | 13 |

| 159 | Analysis of ovarian reserve markers (AMH, FSH, AFC) in different age strata in IVF/ICSI patients. **2016**, 14, 501-506 | 8 |

| 158 | The role of advanced paternal age in modern reproductive medicine. **2016**, 18, 425 | 6 |

| 157 | Effectiveness of Anti-Mullerian Hormone-tailored Protocol Compared to Conventional Protocol in Women Undergoing Fertilization: A Randomized Controlled Trial. **2018**, 11, 24-28 | 2 |

| 156 | Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?. **2017**, 10, 24-30 | 20 |

| 155 | Three-dimensional Ultrasound in the Fertility Clinic. **2008**, 2, 65-74 | 2 |

| 154 | Diminished Ovarian Reserve, Causes, Assessment and Management. **2013**, 4, 45-55 | 4 |

| 153 | Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. **2020**, 18, 200-209 | 3 |

| 152 | miR-4463 regulates aromatase expression and activity for 17Əestradiol synthesis in response to follicle-stimulating hormone. **2020**, 47, 194-206 | 4 |

| 151 | Results of IVF-ICSI cycles in low responder patients: An observational study. **2021**, 8, 100109 | |

| 150 | Fertility evaluation of infertile women: a committee opinion. *Fertility and Sterility*, **2021**, 116, 1255-1265 4.8 | 7 |

| 149 | Correlation analysis of clinical and medical history records of married couples receiving infertility treatment. **2021**, 84-93 | |

148   Development and Validation of Prediction Model for High Ovarian Response in Fertilization-Embryo Transfer: A Longitudinal Study. **2021**, 2021, 7822119   1

147   ULTRASONOGRAPHIC IMAGING IN INFERTILITY. **2008**, 986-1019   1

146   Investigating infertility. **2008**, 52-113

145   The couple with unexplained infertility. **2008**, 251-260

144   The older woman wishing to conceive. **2008**, 273-286

143   Poor Response to Controlled Ovarian Hyperstimulation. **2009**, 37-80

142   [Anti-Mllerian hormone--its role in management of involuntary infertility]. **2009**, 129, 409-11   1

141   Two-dimensional largest ovarian area to predict ovarian response in in vitro fertilization cycle. **2010**, 3, 51

140   Imagerie des Troubles de L'ovulation. **2010**, 175-191

139   Endokrinologische Diagnostik bei Kinderwunsch und regelmen Zyklen. **2010**, 411-416

138   Place de lhographie 2D-3D dans le bilan de linfertilit. **2011**, 225-247

137   Effects of bipolar electrocoagulation versus suture on ovarian reserve after laparoscopic excision of ovarian endometrioma. **2011**, 27, 468-472

136   Infertility, Evaluation, and Treatment. **2011**, 253-265

135   Assisted reproduction treatments. **2011**, 312-334

134   Pre IVF Evaluation of the Infertile Woman. **2012**, 1-15

133   Female Infertility and Fertility Preservation. **2013**, 177-196

132   Patient-Tailored Approaches to Ovarian Stimulation in ART. **2013**, 137-153

131   Selecting and Screening Recipients: Diminished Ovarian Reserve and Premature Ovarian Failure. **2013**, 47-63

130   A Practical Approach to Recent Advances in Ovarian Reserve Testing. **2013**, 51-68

129   Ovarian Reserve and Ovarian Cysts. **2014**, 63-74

128   3D Ultrasound for Follicle Monitoring in ART. **2014**, 263-282

127   Ovarian Reserve in Patients with Endometriosis. **2014**, 419-429

126   Fertility Scoring Index: Cimar's Novel System to Predict assisted Reproductive Technology Success. **2014**, 5, 44-57

125   Outcome of Assisted Reproduction Treatment in Women with Extremely Low Antimullerian Hormone (AMH) Levels. **2014**, 04, 961-966

124   Ovarian reserve after laparoscopic treatment of unilateral ovarian endometrioma. **2014**, 22, 371-3

123   The New Three-dimensional Ultrasound Modes allow a Better Polycystic Ovary Syndrome Ultrasound Diagnosis beyond the Rotterdam Criteria. **2015**, 9, 434-445

122   Evaluation of ovarian reserve in women with type 2 diabetes mellitus. **2015**, 21, 27   1

121   Obesity and Ovarian Aging (Diminished Ovarian Reserve and Menopause). **2015**, 149-159

120   Prediction of Poor Responders and Current Concepts in Management. **2015**, 271-286

119   KIAUŠIDŽREZERVO VERTINIMO METODAI BEI CHIRURGINIO KIAUŠIDŽENDOMETRIOZŠ GYDYMO REIKŠMŠMOTERS VAISINGUMUI. **2015**, 21, 746-751

118   Management of Poor Responders. **2016**, 29-37

117   Implication of ABO Blood Type on Ovarian Reserve in Indian Women. **2016**, 7, 49-51

116   Nomogram of Follicle Stimulating Hormone Starting Dose Based on Antral Follicle Count, Third Day Follicle Stimulating Hormone Levels, and Age in Hasan Sadikin Hospital Bandung. **2016**, 04, 74-85

115   Fertility Assessment in the Female. **2016**, 69-79

114   Preservation of ovarian reserve in patients with endometriosis. **2016**, 22, 37   1

113   RATIONALE OF INCORPORATING SERUM ANTI-MULLERIAN HORMONE ESTIMATIONS IN DIAGNOSING PREMATURE OVARIAN FAILURE. **2016**, 5, 6379-6383

94	Endometrioma: ovarian reserve and management. **2021**, 27, 77	1
93	Mining of variables from embryo morphokinetics, blastocyst's morphology and patient parameters: an approach to predict the live birth in the assisted reproduction service. **2020**, 24, 470-479	1
92	AMH and Medically Assisted Reproduction. **2020**, 31-36	
91	Impact of Age on Hormonal Profiles of Sub-Fertile Women Attending Fertility Clinic in Umuahia, Abia State, South Eastern Nigeria. **2020**, 10, 51-68	
90	Predictive value of ovarian hormone-producing function assessment in poor responders undergoing assisted reproductive technologies. **2019**, 68, 7-18	
89	Review of Infertility Diagnosis and Evaluation. **2021**, 10, 77	
88	Evaluaciñ de la reserva ovñica: pasado, presente y futuro. **2020**, 28, 77-88	
87	A Comparison of Endometrial Thickness and Pregnancy Outcomes in Two Methods of Intrauterine Injection and Subcutaneous Injection of GCSF in Infertile Women Candidates for IVF. **2020**, 5, 39-43	
86	The Gynecologist Has a Unique Role in Providing Oncofertility Care to Young Cancer Patients. **2011**, 6, 24-34	13
85	Comparison of Ovarian volume and Antral follicle count with Endocrine tests for prediction of responsiveness in ovulation induction protocols. **2012**, 1, 71	1
84	Prediction and diagnosis of poor ovarian response: the dilemma. **2011**, 12, 241-8	18
83	Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs. **2009**, 10, 213-9	9
82	Only female age, and not blood type, is associated with ovarian reserve. **2014**, 8, 143-6	7
81	Effect of lower than expected number of oocyte on the IVF results after oocyte-pickup. **2014**, 7, 1853-9	4
80	Prediction of assisted reproductive technique outcome in elevated early follicular phase follicle stimulating hormone with Mullerian inhibiting substance level. **2012**, 10, 201-8	2
79	A case report of spontaneous pregnancy during hormonal replacement therapy for premature ovarian failure. **2011**, 9, 47-9	3
78	Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view. **2009**, 1, 79-87	5
77	Recurrent implantation failure is more frequently seen in female patients with poor prognosis. **2012**, 6, 71-8	2

58	Diminished ovarian reserve in young women with sickle cell anemia. *Blood*, **2021**,	2.2	2
57	Machine Learning-Based Modeling of Ovarian Response and the Quantitative Evaluation of Comprehensive Impact Features.. *Diagnostics*, **2022**, 12,	3.8	1
56	Identification of miR-34-3p as a Candidate Follicular Phase Serum Marker for Endometriosis: a pilot study. *F&S Science*, **2022**,	0.4	
55	Are There Ovarian Responsive Indexes That Predict Cumulative Live Birth Rates in Women over 39 Years?. *Journal of Clinical Medicine*, **2022**, 11,	5.1	0
54	Technological advancement: In vitro fertilization (IVF). *Research Journal of Pharmacy and Technology*, **2021**, 6721-6724	1.7	
53	The putative roles of FSH and AMH in the regulation of oocyte developmental competence: from fertility prognosis to mechanisms underlying age-related subfertility.. *Human Reproduction Update*, **2021**,	15.8	2
52	Ovarian Hyperstimulation Syndrome Risk Factors in Assisted Reproductive Technologies (Review). **2020**, 475-489		
51	Analytical performance evaluation of sensitive and old generation reagent in routine practical use: estradiol experience.. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2022**, 1-6	2	0
50	How to Individualize Ovarian Stimulation Protocols to Avoid Difficulties and Complications. **2022**, 166-172		
49	Ovarian Reserve as a Guide for Ovarian Stimulation. **2022**, 311-318		
48	Assisted reproductive technologies. 48-72		
47	Ultrasound in the investigation of the subfertile female. 60-75		
46	Table_1.docx. **2018**,		
45	A Robotic System with Embedded Open Microfluidic Chip for Automatic Embryo Vitrification.. *IEEE Transactions on Biomedical Engineering*, **2022**, PP,	5	0
44	POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2022**,	4.6	
43	Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis. *Endocrine*,	4	
42	Effect of salpingectomy on ovarian reserve: A systematic review and meta-analysis. *Journal of Obstetrics and Gynaecology Research*,		
41	Identification of lesional attributes of dysmenorrhea severity and the serum antimüllerian hormone levels in women with ovarian endometriomas. *Fertility and Sterility*, **2022**,	4.8	0

40   Fertility Preservation. **2022**, 303-321

39   Ovarian Reserve Testing. **2022**, 323-333

38   Female Infertility Is Associated with an Altered Expression Profile of Different Members of the Tachykinin Family in Human Granulosa Cells. *Reproductive Sciences*,   3

37   The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status. *Reproductive Sciences*,   3

36   Association of AMH and AMHR2 gene polymorphisms with ovarian response and pregnancy outcomes in Indian women. *Journal of Assisted Reproduction and Genetics*,   3.4

35   Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials. *Archives of Gynecology and Obstetrics*,   2.5

34   Basal serum level of 4-androstenedione reflects the ovaries ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response. *Journal of Assisted Reproduction and Genetics*,   3.4

33   An online tool for predicting ovarian reserve based on AMH level and age: A retrospective cohort study. 13,

32   Association of Body Mass Index with Hypothalamus-Pituitary-Ovarian Axis Hormones in Infertile Women in the Niger Delta Region, Nigeria. **2022**, 12, 671-685   0

31   Shortened ovarian stimulation duration may not affect oocyte developmental competence: a retrospective study.   0

30   Kadın İnfertilitesinin Değerlendirilmesi ve Yorumlanması.   0

29   High physical activity and ovarian reserve: a prospective study of normo-ovulatory professional athletes. **2022**, 15,   0

28   Biological Basis of Female Reproductive Aging: What Happens to the Ovaries and Uterus as They Age?. **2022**, 19-26   0

27   Anti-Müllerian Hormone and Follicle-Stimulating Hormone Are Poor Independent Predictors of Live Birth After Assisted Reproductive Technology.   0

26   Serum anti-Müllerian hormone recovery after ovarian cystectomy for endometriosis: A retrospective study among Korean women. **2022**, 101, e30977   0

25   Fertility With Early Reduction of Ovarian Reserve. **2022**,   0

24   Self-reported history of comorbidities and markers of ovarian reserve among subfertile women.   0

23   Comparing the inter-cycle variation of serum anti-Mullerian hormone and antral follicle count measurements over four consecutive menstrual cycles.   0

| 22 | Prediction of ovarian response using the automated Elecsys AMH assay in gonadotropin-releasing hormone antagonist cycles. **2022**, | 0 |

| 21 | To Compare the Research Progress of AMH and bFSH in the Reflection of Ovarian Function and the Predictive Value of Assisted Reproductive Outcomes. **2022**, 12, 10040-10045 | 0 |

| 20 | Feasibility of repeat microdissection testicular sperm extraction within 6 months for non-obstructive azoospermia. Publish Ahead of Print, | 0 |

| 19 | Pregnancy outcomes after oral and injectable ovulation induction in women with infertility with a low antimüllerian hormone level compared with those with a normal antimüllerian hormone level. **2022**, | 0 |

| 18 | Analysis of relative factors and prediction model for optimal ovarian response with gonadotropin-releasing hormone antagonist protocol. 13, | 0 |

| 17 | Impact of elevated body mass index on cumulative live birth rate and obstetric safety in women undergoing assisted reproductive technology. **2022**, 12, | 0 |

| 16 | Pregnancy loss after in vitro fertilization and related factors. **2022**, | 0 |

| 15 | Effects of Levonorgestrel-Releasing Intrauterine Device Therapy on Ovarian Reserve in Menorrhagia. **2022**, | 0 |

| 14 | The estrogen receptor polymorphisms and controlled ovulation hyperstimulation outcomes: a meta-analysis. 1-8 | 0 |

| 13 | Bibliometric analysis and visualization of literature on assisted reproduction technology. 9, | 0 |

| 12 | Significance of oxidative stress and antioxidant capacity (d-ROMs and BAP) tests as biomarkers of premature ovarian insufficiency: a case-control study. | 0 |

| 11 | Evaluation of correlation between antral follicle diameters with Follicular Output Rate (FORT) in women under controlled ovarian hyperstimulation for assisted reproductive techniques. **2022**, 11, | 0 |

| 10 | Oocyte developmental capacity is influenced by intrinsic ovarian factors in a bovine model for individual embryo production. **2023**, 249, 107185 | 1 |

| 9 | Preparing the couple for ART: necessary and unnecessary diagnostic tests. **2023**, 173-189 | 0 |

| 8 | Workup of female infertility. **2023**, 31-39 | 0 |

| 7 | High-Risk genotypes associated with poor response to controlled ovarian stimulation in Indian women. **2023**, 16, 70 | 0 |

| 6 | Retrospective study of ovarian reaction and fertility in women with discordant antimullerian hormone and follicle-stimulating hormone/luteinizing hormone ratios during in vitro fertilization. **2023**, 49, 966-972 | 0 |

| 5 | Impact of Ovarian Endometrioma and Surgery on Reproductive Outcomes: A Single-Center Spanish Cohort Study. **2023**, 11, 844 | 0 |

| 4 | Inflammatory bowel disease can reduce ovarian reserve function in women: A systematic review and meta-analysis. **2023**, 102, e33113 | 0 |

| 3 | The Risk of Infertility After Surgery for Benign Ovarian Cysts. | 0 |

| 2 | Is AMH Prediction of Menopause?. **2023**, 37-41 | 0 |

| 1 | Geographical diversity in the age specific anti Mᵤllerian hormone levels in infertile women: A hospital based cohort study. **2023**, 16, 29 | 0 |